Development of a controlled sustainable anticancer drug delivery nanosystem comprising doxorubicin and functionalized MCM-48

Dasgupta, Debatrayee; Das, Manita; Thakore, Sonal; Patel, Anjali; Kumar, Sunny; Seshadri, Sriram

doi:10.1016/j.jddst.2022.103419

Cited by 8 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7). The spectrum is similar to that of TPA/nMCM-48, 35 indicating that TPA acts as a functionalizing agent and that its structure is retained during drug release. Hence, the system GLP/TPA/nMCM-48 is being considered for further detailed studies including kinetics.…”

Section: Materials Advances Papermentioning

confidence: 64%

Section: Methodsmentioning

confidence: 99%

“…The detailed characterizations related to nMCM-48 and TPA/nMCM-48 are already published by our group; however, for comparison and the reader's convenience some of the characterizations are included here as well. 35 Drug release study. The release curve was established by plotting the amount of drug released with the progression of time.…”

Section: Papermentioning

confidence: 99%

See 2 more Smart Citations

A sustainable nano drug delivery system for poorly soluble drug, glipizide: design, in vitro controlled release and kinetics

Dasgupta

Patel

2022

Mater. Adv.

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Materials Advances Papermentioning

confidence: 64%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

A sustainable nano drug delivery system for poorly soluble drug, glipizide: design, in vitro controlled release and kinetics

Dasgupta

Patel

2022

Mater. Adv.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The decrease in the absolute value of the zeta potential could be due to an electrostatic interaction between the nanocarrier and Dox. It is well known that Dox is a cationic drug (pKa = 8.3) which is positively charged in physiological conditions due to the presence of amine groups [ 51 , 52 ]. The results for the average size are in agreement with the TEM analysis.…”

Section: Resultsmentioning

confidence: 99%

Thermosensitive Hydrogel-Functionalized Mesoporous Silica Nanoparticles for Parenteral Application of Chemotherapeutics

Voycheva,

Slavkova,

Popova

et al. 2023

Gels

View full text Add to dashboard Cite

Hydrogels can offer many opportunities for drug delivery strategies. They can be used on their own, or their benefits can be further exploited in combination with other nanocarriers. Intelligent hydrogels that react to changes in the surrounding environment can be utilized as gatekeepers and provide sustained on-demand drug release. In this study, a hybrid nanosystem for temperature- and pH-sensitive delivery was prepared from MCM-41 nanoparticles grafted with a newly synthesized thermosensitive hydrogel (MCM-41/AA-g-PnVCL). The initial particles were chemically modified by the attachment of carboxyl groups. Later, they were grafted with agar (AA) and vinylcaprolactam (VCL) by free radical polymerization. Doxorubicin was applied as a model hydrophilic chemotherapeutic drug. The successful formulation was confirmed by FT-IR and TGA. Transmission electron microscopy and dynamic light scattering analysis showed small particles with negative zeta potential. Their release behaviour was investigated in vitro in media with different pH and at different temperatures. Under tumour simulating conditions (40 °C and pH 4.0), doxorubicin was almost completely released within 72 h. The biocompatibility of the proposed nanoparticles was demonstrated by in vitro haemolysis assay. These results suggest the possible parenteral application of the newly prepared hydrogel-functionalized mesoporous silica nanoparticles for temperature-sensitive and pH-triggered drug delivery at the tumour site.

show abstract

“…As an alternative to systemic adjuvant therapy, local drug delivery systems (DDSs) [5,[9][10][11] have been designed to be implanted directly into the tumor bed after surgery and provide sustained drug release to the tumor site, which can overcome drug transport barriers and reduce side effects as well as improve patient adherence [12] DDSs are responsible for drug delivery in a specific way, either by attacking tumor cells directly and exclusively or by leading conventional drugs to the affected organ [11]. Some examples of DDSs are patches [13,14], hydrogels [15,16], nanoparticles, even using new carriers such as MCM-41, MCM-48, or SBA-15 [17][18][19][20][21], or electrospun meshes [8,9,[22][23][24]. Compared to traditional systemic or regional chemotherapy, local administration of the drug using a drug-eluting scaffold reduces the dose required to achieve a comparable anti-cancer effect by approximately two-thirds [8].…”

Section: Introductionmentioning

confidence: 99%

TARTESSUS: A Customized Electrospun Drug Delivery System Loaded with Irinotecan for Local and Sustained Chemotherapy Release in Pancreatic Cancer

et al. 2023

View full text Add to dashboard Cite

Post-surgical chemotherapy in pancreatic cancer has notorious side effects due to the high dose required. Multiple devices have been designed to tackle this aspect and achieve a delayed drug release. This study aimed to explore the controlled and sustained local delivery of a reduced drug dose from an irinotecan-loaded electrospun nanofiber membrane (named TARTESSUS) that can be placed on the patients’ tissue after tumor resection surgery. The drug delivery system formulation was made of polycaprolactone (PCL). The mechanical properties and the release kinetics of the drug were adjusted by the electrospinning parameters and by the polymer ratio between 10 w.t.% and 14 w.t.% of PCL in formic acid:acetic acid:chloroform (47.5:47.5:5). The irinotecan release analysis was performed and three different release periods were obtained, depending on the concentration of the polymer in the dissolution. The TARTESSUS device was tested in 2D and 3D cell cultures and it demonstrated a decrease in cell viability in 2D culture between 72 h and day 7 from the start of treatment. In 3D culture, a decrease in viability was seen between 72 h, day 7 (p < 0.001), day 10 (p < 0.001), 14 (p < 0.001), and day 17 (p = 0.003) as well as a decrease in proliferation between 72 h and day 10 (p = 0.030) and a reduction in spheroid size during days 10 (p = 0.001), 14 (p < 0.001), and 17 (p < 0.001). In conclusion, TARTESSUS showed a successful encapsulation of a chemotherapeutic drug and a sustained and delayed release with an adjustable releasing period to optimize the therapeutic effect in pancreatic cancer treatment.

show abstract

Development of a controlled sustainable anticancer drug delivery nanosystem comprising doxorubicin and functionalized MCM-48

Cited by 8 publications

References 32 publications

A sustainable nano drug delivery system for poorly soluble drug, glipizide: design, in vitro controlled release and kinetics

A sustainable nano drug delivery system for poorly soluble drug, glipizide: design, in vitro controlled release and kinetics

Thermosensitive Hydrogel-Functionalized Mesoporous Silica Nanoparticles for Parenteral Application of Chemotherapeutics

TARTESSUS: A Customized Electrospun Drug Delivery System Loaded with Irinotecan for Local and Sustained Chemotherapy Release in Pancreatic Cancer

Contact Info

Product

Resources

About